First-pass extracted concept

chimeric antigen receptor engineered immune cells

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

CAR-based therapies, CAR engineered immune cells

Evidence Snippets

Therapies utilizing chimeric antigen receptor (CAR) engineered immune cells have emerged as a promising and potentially curative approach.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1clinical outcomesupports2025Source 1DOI PubMed

Clinical trials targeting CD19-expressing B cells in B-cell-driven autoimmune diseases such as systemic lupus erythematosus have shown encouraging results with durable remissions in otherwise treatment-resistant cases.

Claim 2limitationsupports2025Source 1DOI PubMed

Current CAR-based autoimmune therapies face short- and long-term safety concerns, limited in vivo persistence, and high costs associated with personalized cell manufacturing.

Claim 3therapeutic promisesupports2025Source 1DOI PubMed

CAR-engineered immune cell therapies have emerged as a promising and potentially curative approach for autoimmune diseases.